Neurobehavioural deficits following postnatal iron overload: II instrumental learning performance

Neurotoxicity Research

Volumn 5, Issue 1-2, 2003, Pages 77-94

  Archer, Trevor ^a   Schoroder N ^b   Fredriksson, A ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Acquisition; Basal ganglia; C57 BL6 mice; Cerebellum; Iron administration; NMRI mice; Oxidative Stress enzymes; Parkinsonism; Radial maze; Rats; Retention quotients; Striatum; Substantia nigra; Superoxide dismutase; TBARS

Indexed keywords

IRON; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL; ARTICLE; BRAIN; DRUG EFFECT; EXPLORATORY BEHAVIOR; FEMALE; IRON OVERLOAD; MALE; MAZE TEST; MEMORY; METABOLISM; MOTOR ACTIVITY; MOUSE; NEWBORN; OXIDATIVE STRESS; PREGNANCY; PSYCHOLOGICAL ASPECT; RAT; SUBSTANTIA NIGRA; WEIGHT GAIN; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; BRAIN; EXPLORATORY BEHAVIOR; FEMALE; IRON; IRON OVERLOAD; MALE; MAZE LEARNING; MEMORY; MICE; MOTOR ACTIVITY; OXIDATIVE STRESS; PREGNANCY; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; THIOBARBITURIC ACID REACTIVE SUBSTANCES; WEIGHT GAIN;

EID: 17344376817     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033374     Document Type: Article

References (98)

1. Aebi H (1984) Catalase in vitro. Methods Enzymol. 105, 121-126.
2. Ames BN, MK Shigenaga and TM Hagen (1993) Oxidants, antioxidants and the degenerative disease of aging. Proc. Natl. Acad. Sci. USA 90, 7915-7922.
3. Archer T, RJ Beninger, TUC Järbe and LS Seiden (1990) Letent tearnning in a radial arm maze following neonatal dopamine depletion. Behav. Pharmacol. 1, 191-199.
4. Asanuma M, H Hirata and JL Cadet (1998) Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice. Neuroscience 85, 907-917.
5. Bannister JV and L Calabrese (1987) Assays for SOD. Methods Biochem. Anal. 32, 279-312.
6. Belova TI and G. Jonson (1982) Blood-brain barrier permeability under immobilization stress. Acta Physiol. Scand. 116, 21-29.
7. Ben-Schachar D and MB Youdim (1991) Intranigral iron injection induces behavioural and biochemical "parkinsonism" in rats. J. Neurochem. 57, 2133-2135.
8. Ben-Schachar D, G. Eshel, JP Finberg, D Ben-Schachar and MB Youdim (1991) The iron chelator desferroxamine (Desferal) rerards 6-hydroxydopamine-induced degeneration of nigrostriaral dopamine neurons. J. Neurochem. 56, 1441-1444.
9. Bolles RG and PJ Woods (1964) The ontogeny of behaviour in the albino rat. Anim, Behav. 12, 427-441.
10. Bostantjopoulou S, G Kyriazis, Z. Katsarou, G Kiosseoglou, A Kazis and G Mentenopoulos (1997) Superoxide dismutase activity in early and advanced Parkinson's disease. Funct. Neurol. 12, 63-68.
11. Cadenas E and KJA Davies (2000) Mitochondrial free radical generation. oxidative stress, and aging. Free Radic. Biol. Med. 29, 222-230.
12. Campbell BA, LD Lytle and HC Fibiger (1969) Ontogeny of adrenergic arousal and cholinergic inhibitory mechanisms in the rat. Science 166, 635-637.
13. Chiueh CC, H Miyake and MT Peng (1993) Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism Adv. Neurol. 60, 251-258.
14. Chiueh CC, YL Sang, T Andoh, AR Lai, E Lai and G Krishna (2000) Neuroprotective strategies in Parkinson's disease: Protection against progressive nigral damage induced by free radicals, In: Palomo T, RJ Beninger and T Archer, Eds., Neurodegenerative Brain Disorders. (Fundación Cerebro y Mente, Madrid, Spain), pp 565-586.
15. Connor JR, G Pavlick, D Karli, SL Menzies and C Palmer (1995) A histochemical study of iron-positive cells in the developing rat brain. J. Comp. Neurol. 355, 111-123.
16. Dal-Pazzol F, F Klamt, MLC Frota, ME Andrades, FF Caregnato, MMR Vianna, N Schröder, J Quevedo, I Izquierdo, T Archer and JC Moreira, Jr (2001) Neonatal iron exposure induces oxidative stress in adult Wistar rat. Brain Res. Dev. Brain Res. 130, 109-114.
17. Davison AN and J Dobbing (1968) Applied Neurochemistry (Blackwell, Oxford).
18. Dexter DT, FR Wells, F Agid, Y Agid, AJ Lees, P Jenner and CD Marsden (1987) Increased nigral iron content in postmortem parkinsonian brain [letter]. Lancet 2, 1219-1220.
19. Dexter DT, A Carayon, F Javoy-Agid, Y Agid, FR Wells, SE Daniel, AJ Lees, P Jenner and CD Marsden (1991) Alterations in the level of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
20. Double KL, M Maywald, M Schmittel, P Riederar and M Gerlach (1998) In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70, 2492-2499.
21. Drayer BP, CW Olanow, P Burger, GA Johnson, R Herfkens and PS Riederer (1986) Parkinson plus syndrome: Diagnosis using high field MR imaging of brain iron. Radiology 159 493-498.
22. Dwork AJ, G Lawler, PA Zybert, M Durkin, M Osman, N Willson and AL Barkai (1990) An autoradiographic study of the uptake and distribution of iron by the brain of the young rat. Brain Res. 518, 31-39.
23. Esterbauer H and KH Cheeseman (1990) Determination of aldehydic lipid peroxidation products: Malondialehyde and 4-hydrononenal. Methods Enzymol. 186, 407-421.
24. Evans P (1993) Free radicals in brain metabolism and pathology. Br. Med. Bull. 49, 577-587.
25. Faucheux BA, MT Herrero, J Villares, R Levy, F Javoy-Agid, JA Obeso, JJ Hauw, Y Agid and EC Hirsch (1995) Autoradiographic localization and density of [125 l] ferrotransferrin hinding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys. Brain Res. 691, 115-124.
26. Fellman V J Rapola, H Pihko, T Varilo and KO Raivio (1998) Ironoverload disease in infants involving fetal growth retardation lactic acidosis, liver haemosiderosis, and aminoaciduria [see comments]. Lancet 351, 490-493.
27. Fredriksson A and T Archer (1997) Alpha-phenyl-tert-butyl-nitrone (PBN) reverses age-related maze learning performance and motor activity deficits in mice. Behav. Pharmacol. 7, 1-9.
28. Fredriksson A and T Archer (2003) Effect of postnatal iron administration on MPTP-induced behavioural deficits and neurotoxicity: Behavioural enhancement by L-Dopa-MK-801 co-administration. Behav. Brain Res. in press.
29. Fredriksson A, N Schröder, P Eriksson, I Izquierdo and T Archer (1999) Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol. Appl. Pharmacol. 159, 25-30.
30. Fredriksson A, N Schröder, P Eriksson, I Izquierdo and T Archer (2000) Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period. Brain Res. Dev. Brain Res. 119, 65-74.
31. Fredriksson A, N Schröder, P Eriksson, I Izquierdo and T Archer (2001) Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism Rel. Dis. 7, 97-105.
32. Gerlach M and P Riederer (1999) Time sequences of dopaminergic cell death in Parkinson's disease. Indications for neuroprotective studies. Adv. Neurol. 80, 219-225.
33. Gerlach M, D Ben-Shachar, P Riederer and MBH Youdim (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J. Neurochem. 63, 793-807.
34. Gerlach M, P Riederer and MBH Youdim (1996) Molecular mechanisms for neurodegeneration: Synergism between reactive oxygen species, calcium and the excitotoxic amino acids. Adv. Neurol. 69. 177-194.
35. Gerlach M, KL Double, MBH Youdim and P Riederer (2000) Strategies for the protection of dopaminergic neurons against neurotoxicity, In: Palomo T, RJ Beninger and T Archer,Eds. Neurodegenerative Brain Disorders (Fundación Cerebro y Mente, Madrid, Spain), pp 587-607.
36. Glowinski J and LL Iversen (1966) Regional studies of catecholamines in the rat brain. I. The disposition of [3 H]norepinephrine, [3 H] dopamine and [3 H]dopa in various regions of the brain. J. Neurochem. 13, 655-669.
37. Götz ME, G Künig, P Riederer and MBH Youdim (1994) Oxidative stress: Free radical production in neural degeneration. Pharmacol. Ther. 63, 37-122.
38. Hall S, JH Rulledge and T Schallert (1992) MRI brain iron and 6-hydroxydopamine experimental Parkinson's disease. J. Neurol. Sci. 113, 198-208.
39. Halliwell B (1992) Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623.
40. Halliwell B and JM Gutteridge (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219, 1-14.
41. Harris RL, Y Takahashi, H Miyajima, M Serizawa, TA McGillivary and JD Gitlin (1995) Aceruloplasminemia: Molecular characterisation of this disorder of iron metabolism. Proc. Natl. Acad. Sci. USA 92, 2539-2543.
42. He Y, PS Thong, T Lee, SK Leong, CY Shi, PT Wong, SY Yuan and F Watt (1996) Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: A nuclear micrioscopy study. Brain Res. 735, 149-153.
43. Ibara Y, M Chuda, S Kuroda and T Haybara (1999) Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. J. Neurol. Sci. 170, 90-95.
44. Ikonomidou C, P Bittigau, MJ Ishimaru, DF Wozniak, C Koch, K Genz, MT Price, V Stefovska, F Hörster, T Tenkova, K Dikranian and JW Olney (2000) Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 287, 1056-1060.
45. Izquierdo I (1989) Different forms of posttraining memory processing. Behav. Neural Biol. 51, 171-202.
46. Janetzky B, H Reichmann, MBH Youdim and P Riederer (1997) Iron and oxidative damage in neurodegenerative diseases, In: Beal MF, H Howell, I Bodis-Wollner (Eds.). Mitochondria and Free Radicals in Neurodegenerative Diseases (Willay-Liss, New York), pp 407-421.
47. Jellinger KA (1999) The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14, 115-140.
48. Jenner P and CW Olanow (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, 161-170.
49. Jonsson G (1983) Chemical lesioning techniques: Monoamine neurotoxins, In: Björklund A and T Hökfelt (Eds.), Handbook of Chemical Neuroanatomy, Vol. I Methods (Elsevier, Amsterdam), pp. 463-507.
50. Kerr JFR, AH Wyllie and AR Currie (1972) Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 265 239-245.
51. Kienzl E, L Puchinger, K Jellinger, W Linert, H Stachelberger and PF Jameson (1995) The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 134(Suppl,) 69-78.
52. Kinloch RA, JM Treherne, LM Furness and I Hajimohamadreza (1999) The pharmacology of apoptosis. TIPS 20, 35-42.
53. Kirk R (1995) Experimental Design: Procedures for the Behavioural Sciences (Brooks/Cole, Belmont, CA).
54. Lan J and DH Jiang (1997) Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104, 649-660.
55. Lan J and DH Jiang (1997b) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. 104, 469-481.
56. Linert W, E Herlinger, RF Jameson, E Kienzl, K Jellinger and MBH Youdim (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316, 160-168.
57. Loeffler DA, PA LeWitt, PL Juneau, AF Sima, H-U Nguyen, AJ DeMaggio, CM Brickman, GJ Brewer, RD Dick, MD Troyer and L Kanaley (1996) Increased regional concentration of ceruloplasmin in neurodegenerative disorders. Brain Res. 738, 265-274,
58. Logroscino G, K Marder, J Graziano, G Freyer, V Slavkovich, N Loiacono, L Cote and R Mayen (1997) Altered systemie iron metabolism in Parkinson's disease. Neurology 49, 714-717.
59. Martignoni E, F Blandini, L Godi, S Desideri, C Pacchetti, F Mancini and G Nappi (1999) Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA. Free. Radic. Biol. Med. 27, 428-437.
60. Mash DC, J Pablo, BE Buck, J Sanchez-Ramos and WJ Weiner (1991) Distribution and number of transferrin teceptors in Parkinson's disease and in MPTP-treated mice. Exp. Neurol. 114, 73-81.
61. Mohanakumar KP, A de Bartolomeis, RM Wu, KJ Yeh, LM Sternberger, SY Peng, DL Murphy and CC Chiueh (1994) Ferrous-citrate complex and nigral degeneration: Evidence for freeradical formation and lipid peroxidation. Ann. NY acad. Sci. 738, 329-399.
62. Monteiro HP and CC Winterbour (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38, 4177-4182.
63. Nagatsu T and L Starne (1998) Catecholamine synthesis and release. Overview. Adv. Pharmacol. 42, 1-14.
64. Olanow CW, G Cohen, DP Perl and CD Marsden (1992) Role of iron and oxidant stress in the normal and parkinsonian brain. Ann. Neurol. 32, S1-S145.
65. Olanow CW, PF Good, H Shinotoh, KA Hewitt, F Vingerhoets, BJ Snow, MF Beal, DB Calne and DP Perl (1996) Mangarese intoxication in the rhesus monkey: A clinical, imaging, pathologic, and biochemical study. Neurology 46, 492-498.
66. Olton DS and MA Werz (1978) Hippocampal function and behavior: Spatial discrimination and response inhibition. Physiol. Behav. 20, 597-605.
67. Olton DS, JA Walker and FH Gage (1978) Hippocampal connections and spatial discrimination. Brain Res. 139, 295-308.
68. Poirer J and A Barbeau (1987) MPTP potentiates iron-induced lipid peroxidation without the involvement of free radicals dirived from oxygen. Res. Commun. Chem. Pathol. Pharmacol. 56, 387-399.
69. Przedborski S, V Kostic, D Jackson-Lewis, AB Naini, S Simonetti, S Fahn, E Carlson, CJ Epstein and JL Cader (1992) Transgenic mice with increased Cu/Zn superoxide dismutase activity are resistent to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12, 1658-1667.
70. Rakic P and PS Goldman-Rakic (1982) The development and modifiability of the cerebral cortex. Neurosci. Res. Progr. Bull 20, 433-438.
71. Rauhala P, I Sziraki and CC Chiueh (1996) Peroxidation of brain lipids in vitro: Nitiric oxide versus hydroxyl raicals. Free Radic. Biol. Med. 21, 391-394.
72. Reichmann H, B Janetzky and P Riederer (1995) Iron-dependent enzymes in Parkinson's disease. J. Neural Transm. (Suppl.) 46, 157-164.
73. Riederer P, E Sofic, WD Rausch, B Schmidt, GP Reynolds, K Jellinger and MB Youdim (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
74. Rötig A, P de Lonlay, D Chretien, F Foury, M Koenig, D Sidi, A Munnich and P Rustin (1997) Aconitase and mitochondrial ironsulphur protein deficiency in Freidreich ataxia. Nat. Genet. 17, 215-217.
75. Rozenzweig, MR, AL Leiman and SM Breedlove (1999) Biological Psychology: An Introduction to Behavioral, Cognitive and Clinical Neuroscience Sinauer Assoc, Inc., Sunderland, MA, USA).
76. Rustin P JC von Kleist-Retzow, A Rotig and A Munnich (1998) Iron overload and mitochondrial diseases [letter; comment]. Lancet 351, 1286-1287.
77. Sachs C (1973) Development fo the blood-brain barrier for 6-hydroxydopamine. J. Neurochem. 20, 1753-1760.
78. Sachs C and G Jonsson (1975) 5, 7-Dihydroxytryptamine induced lesions in the postnatal development of central 5-hydroxydopamine neurons. Med. Biol. 53, 156-164.
79. Sandy MS, D Di Monte, P Cohen and MT Smith (1988) Role of active oxygen in paraquat and 1-methyl-4-phenly-1,2,3,6-tetrahydropyridine (MPTP) cytotoxicity. Basic Life Sci. 49, 795-801.
80. Schmidt WJ and BD Kretschmer (1997) Behavioural pharmacology of glutamate receptors in teh basal ganglia. Neurosci. Biobehav. Rev. 21, 381-392.
81. Schröder N, A Fredriksson, MRM Vianna, R Roesler, I Izquierdo and T Archer (2001) Memory deficits in adult rats following postnatal iron administration. Behav. Brain Res. 124 77-85.
82. Sengstock GJ, CW Olanow, RA Menzies, AJ Dunn and GW Arendash (1993) Infusion of iron into the rat substantia nigra: Nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35, 67-82.
83. Sian J, M Gerlach, MBH Youdim and P Riederer (1999) Parkinson's disease: a major hypokinetic basal ganglia disorder. J. Neural Transm. 106, 443-476.
84. Sobotka TJ, P Whittaker, JM Sobotka, RE Brodie, DY Quander, M Robl, M Bryant and CN Barton (1996) Neurobehavioral dysfunctions associated with dietary iron overload. Physiol. Behav. 59, 213-219.
85. Sofic E, W Paulus, K Jellinger, P Riederer and MBH Youdim (1991) Selective increase of iron in substantia nigra of patients with Parkinson's disease: An x-ray microanalysis. J. Neurochem. 56, 446-451.
86. Sofic E, KW Lang, K Jellinger and P Riederer (1992) Reduced and oxidized GSH in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130.
87. Strong R, M Mattamal and A Andorn (1993) Free radicals, the aging brain, and age-related neurodegenerative disorders, In: Yu B (Ed.), Free Radicals in Aging (CRC Press, Boca Raton, FL, USA), pp 223-246.
88. Sziräki I, KP Mohanakumar, P Rauhala, HG, Kim, KJ Yeh and CC Chiueh (1998) Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of Parkinsonism. Neuroscience 85, 1101-1111.
89. Sziráki I, P Rauhala, KK Koh, P van Bergen and CC Chiueh (1999) Implications for atypical antioxidative properties of manganese in iron-induced brain lipid peroxidation and copper-dependent low density lipoprotein conjugation. Neurotoxicology 20, 455-466.
90. Taylor EM and EH Morgan (1990) Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res. Dev. Brain Res. 55, 35-42.
91. Taylor EM, A Crowe and EH Morgan (1991) Transferrin and iron uptake by the brain: Effects of altered iron status. J. Neurochem. 57, 1584-1592.
92. Temlett JA, JP Landsberg, F Watt and GW Grime (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: Evidence from proton microprobe elemental microanalysis. J. Neurochem. 62, 134-146.
93. Tolmasoff JM, T Ono and RG Cutler (1980) Superoxide dismutase: correlation with lifespan and specific metabolic rate in primate species. Proc. Natl. Acad. Sci. USA 77, 2777-2781.
94. Urakami K, K Sano, E Matsushima, A Okada, H Saito, K Takahashi, J Ikebuchi, T Mura and S Ikawa (1992) Decreased superoxide dismutase activity in erythrocytes in Parkinson's disease. Jpn. J. Psychiatr. Neurol. 46, 933-936.
95. Walshe JM and DW Cox (1998) Effect of treatment of Wilson's disease on natural history of haemochromatosis. Lancet 352, 112-113.
96. Watt F (1996) Nuclear microscope analysis in Alzheimer's and Parkinson's disease: A review. Cell Mol. Biol. 42, 17-26.
97. Youdim MBH, D Ben-Shachar and P Riederer (1991) Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur. Neurol. 31, 34-40.
98. Youdim MBH, D Ben-Shachar and P Riederer (1993) The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8, 1-12.